The Science Catches Up With Science

CVT: AstraZeneca IS more dangerous than Pfizer's mRNA 'vaccine'

I told you so. Well, actually, science told you so, almost exactly a year ago. I just related what actual science said. It’s only taken 12 months for the politicised Science-based narrative to reluctantly catch up with the facts. Hence we have this paper, published on 18th May 2022.

Here’s what I said way back in ye olden dayes:

REVEALED: WHY THE OXFORD ASTRAZENECA JAB IS EVEN MORE DANGEROUS THAN THE MRNA ‘VACCINES’

People are dying and suffering from serious illness, including strokes, brain haemorrhages, blood clotting, blindness, heart attacks, neurological/nervous disorders, etc. soon after getting jabbed with any of the ‘vaccines’ currently available in the UK – Pfizer, Moderna and Oxford/AstraZeneca. This is a fact. 44 year old BBC presenter Lisa Shaw has just died from a blood clot, having been injected with AZ’s viral vector ‘vaccine’ – as part of a scandalously coerced mass vaccination program, in violation of the Nuremberg Code, fully supported by and sold to a gullible, fearful public by her own employer. The AZ jab definitely appears to be – at present – the worst offender as far as serious adverse reactions are concerned.

We now have emerging research which might explain why the adenovirus vectored Oxford AZ DNA jab is even more dangerous than the mRNA Pfizer and Moderna jabs. It has to do with the genetically modified chimpanzee adenovirus itself and the way in which it gets its ‘payload’ of SARS-Cov-2 spike encoding DNA into our cells.

The authors of that emerging research postulated that faulty, soluble spike proteins were being transcribed by the DNA in the AZ vaccine:

In simple translation, what the authors are saying here is that because the AZ and other ‘vaccines’ deliver a piece of DNA (not mRNA) directly into the cell nucleus via the adenovirus vector, then there is the possibility that errors will occur when that DNA is transcribed back into RNA inside the nucleus. Thus, when the RNA is expelled from the nucleus into the surrounding cell material and starts instructing the cell machinery to manufacture the SARS-CoV-2 spike protein, those spike proteins produced might be ‘missing bits’; they will be shorter versions of the actual spike protein which, as result, will be able to migrate into the blood vessels where they will bind to platelets and cause serious health issues, namely haemorrhaging and clotting, which is exactly what we are seeing with AZ adverse reactions.

But that’s not the whole story. We now know for sure that bio-distribution studies prove that the spike protein is widely distributed throughout the body, via the circulatory system, even in the mRNA ‘vaccines’. So blood-borne spike has the potential to cause serious problems in both the mRNA and adenovirus-vector ‘vaccines’. It was fairly certain this was the case even a year ago, as I pointed out:

Unfortunately, spike proteins ‘leaking’ into the blood system can and do happen with other type ‘vaccines’ also, so it’s not a problem unique to AstraZeneca. The mRNA ‘vaccines’, though apparently less dangerous than the Oxford AZ viral vector vaccine, still have a whole host of serious side effects including thrombotic events like clots, strokes, heart attacks, haemorrhages, many linked to thrombocytopenia (low blood platelet count). Something which the manufacturers said couldn’t happen, has happened: spike proteins have been detected circulating in the blood of several volunteers who were administered the Moderna ‘vaccine’.

So that’s spike-induced thrombosis and thrombocytopenia. But with the AZ ‘vaccine’ we have an additional problem, namely the adenovirus vector itself:

That’s all OK then. What they don’t tell you, probably because they didn’t read the study carefully, assuming they even read it at all, is that this newly identified faulty transcription of DNA to RNA, resulting in the production of truncated, soluble spike proteins, is not the only problem with the viral vector ‘vaccines’. The other major problem is the genetically modified adenovirus vector itself. It too can bind to platelets and cause thrombocytopenia. The issue has been known about for at least 15 years, so there’s no excuse for the manufacturers to claim that such an adverse effect was unforeseen – it wasn’t. Here for instance:

Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors. The mechanism underlying this phenomenon is currently unknown.

What this clearly tells us is that there are two major problems with the AZ viral vector vaccine, giving rise to very similar serious thrombotic adverse reactions associated with a low blood platelet count and those two problems arise separately as a result of SARS-CoV-2 spike proteins migrating into the blood, plus the adenovirus itself binding to blood platelets.

It was indeed clear a year ago. All that’s changed since is that a lot more people have been injured and killed from both types of ‘vaccines’ and the FDA has now licensed the mRNA junk to be injected for the third time into the arms of 5-11 year olds. That’s what they call ‘progress’.

So now, a year later, a team of South Koreans bowl up and tell us exactly what we knew a year ago, and I guess this also would be called ‘progress’.

But it’s not. I know this because the authors start off by stating as fact that which is a scientific impossibility with the current ‘vaccines’:

Herd immunity is important for the prevention and suppression of the spread of COVID-19, and vaccination is an essential requirement for herd immunity.

This is complete bullshit I’m afraid, easily disproved by the facts. The ‘vaccines’ are in fact preventing us from getting to herd immunity. There’s more:

We hypothesized that COVID-19 vaccines, particularly mRNA-based COVID-19 vaccines, are related to an increased risk of CVT in real-world settings. Therefore, we aimed to perform a disproportionality analysis to investigate the potential safety signals of mRNA-based COVID-19 and ChAdOx1 nCoV-19 vaccines and the clinical characteristics of CVT following these vaccinations using the World Health Organization’s (WHO) global pharmacovigilance database of individual case safety reports: VigiBase.

They hypothesized? Are you kidding? This information has been out there for over a year. It’s a matter of fact and observation, not a hypothesis. Good grief. We’re way past the point of hypothesizing when it comes to serious adverse reactions. Nevertheless, let’s take a look at the science which they do manage to do, regardless of the politics.

The key findings of our study of CVT cases from VigiBase reported by 130 countries are that the potential safety signal for the development of CVT was noted in mRNA-based COVID-19 vaccines as well as the ChAdOx1 nCoV-19 vaccine compared with the entire dataset.

There are few reports on CVT after mRNA-based COVID-19 vaccination [17,28]. These studies suggested that CVT occurrences related to mRNA-based COVID-19 vaccines may be due to endothelial dysfunction caused by spike glycoprotein interactions with endothelial cells resulting in immunothrombosis. If the spike glycoprotein of mRNA-based COVID-19 vaccines binds to the angiotensin-converting enzyme 2 receptor, several inflammatory and thrombogenic molecules, such as leukocyte chemotactic factors, cell adhesion molecules (vascular cell adhesion molecule 1 and intercellular adhesion molecule 1), and procoagulant cytokines, can be activated. This mechanism may cause endothelial dysfunction, particularly in brain endothelial cells [29], which could contribute to a significant disruption of brain endothelial barrier integrity, ultimately promoting thrombus formation. Moreover, a previous study suggested that the spike glycoprotein may induce platelet aggregation and activation and eventually result in thrombus formation [30]. Although the period of time in which the spike glycoprotein persists has not been clearly established, several studies have suggested that it may last for weeks. Thus, spike glycoprotein-related platelet activation triggered by mRNA-based COVID-19 vaccines could explain the trend of CVT occurrences after mRNA-based COVID-19 vaccinations [30,31]. Furthermore, in line with these previous case reports, our results showed that CVT occurred mainly within a few weeks of mRNA-based COVID-19 vaccinations.

So there’s your spike-induced mechanism for thrombosis and CVT, in the mRNA ‘vaccines’ specifically. But here’s what the authors find with regard to the AstraZeneca jab:

Fewer CVT patients died after receiving mRNA vaccines than after receiving the ChAdOx1 nCoV-19 vaccine (odds ratio, 0.32; 95% CI, 0.22–0.45; p < 0.001).

There are few reports on CVT after mRNA-based COVID-19 vaccination [17,28]. These studies suggested that CVT occurrences related to mRNA-based COVID-19 vaccines may be due to endothelial dysfunction caused by spike glycoprotein interactions with endothelial cells resulting in immunothrombosis. If the spike glycoprotein of mRNA-based COVID-19 vaccines binds to the angiotensin-converting enzyme 2 receptor, several inflammatory and thrombogenic molecules, such as leukocyte chemotactic factors, cell adhesion molecules (vascular cell adhesion molecule 1 and intercellular adhesion molecule 1), and procoagulant cytokines, can be activated. This mechanism may cause endothelial dysfunction, particularly in brain endothelial cells [29], which could contribute to a significant disruption of brain endothelial barrier integrity, ultimately promoting thrombus formation. Moreover, a previous study suggested that the spike glycoprotein may induce platelet aggregation and activation and eventually result in thrombus formation [30].

In agreement with the well-known relationship between the ChAdOx1 nCoV-19 vaccine and CVT [32,33], our results showed a potential safety signal of the ChAdOx1 nCoV-19 vaccine for CVT. Additionally, in one recent study, about 90% of CVT cases following COVID-19 vaccination occurred after the administration of the ChAdOx1 nCoV-19 vaccine [15]. The ChAdOx1 nCoV-19 vaccine can cause systemic thromboembolism due to thrombosis with thrombocytopenia syndrome [34]. The Food and Drug Administration has found a causal link between the adenovirus vector COVID-19 vaccine and thrombosis with thrombocytopenia syndrome and has provided updates on rare clotting or thrombotic events following adenovirus vector COVID-19 vaccination, primarily in young women [35].

So, the authors’ study basically demonstrates what is already known. All they’ve really done is find some differences in the frequency, onset and seriousness of CVT following administration of AZ vs. Moderna/Pfizer mRNA ‘vaccines’.

Interestingly, our results showed that there was a difference in the onset of CVT after exposure to the mRNA-based COVID-19 vaccines and ChAdOx1 nCoV-19 vaccine. The median values of 13 and 11 days for the time to onset of CVT for the mRNA-based COVID-19 vaccines and the ChAdOx1 nCoV-19 vaccine, respectively, were similar. However, the mRNA-based COVID-19 vaccines had the highest number of CVT cases in the first week after vaccination, after which the incidence decreased gradually. In contrast, the ChAdOx1 nCoV-19 vaccine showed the highest incidence of CVT in the second week after vaccination and a sharp decrease thereafter. These timelines suggest that the thrombosis mechanisms of these vaccines differ.

In our study, the number of deaths in CVT patients was lower after mRNA vaccination than after vaccination with ChAdOx1 nCoV-19. A previous study showed that significant risk factors for mortality due to thrombosis with thrombocytopenia syndrome after ChAdOx1 nCoV-19 vaccination were intracerebral hemorrhage and CVT [46]

All in all, this latest study of thrombosis and thrombocytopenia following administration of Covid ‘vaccines’, in particular the incidence of CVT, leaves us slightly better informed but none the wiser